A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer

Publisher： Karger

E-ISSN： 1423-0232|56|4|267-273

ISSN： 0030-2414

Source： Oncology, Vol.56, Iss.4, 1999-05, pp. : 267-273

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study

By  

Oncology, Vol. 80, Iss. 3-4, 2011-07 ,pp. : 238-246

Karger

Access to resources Recommend Favorite

Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents

By  

Oncology, Vol. 84, Iss. 3, 2012-12 ,pp. : 158-165

Karger

Access to resources Recommend Favorite

Topotecan and Gemcitabine in Platinum/Paclitaxel-Resistant Ovarian Cancer

By  

Oncology, Vol. 60, Iss. 1, 2000-12 ,pp. : 19-23

Karger

Access to resources Recommend Favorite

Phase I Study of High-Dose Epirubicin in Platinum-Pretreated Patients with Ovarian Carcinoma

By  

Oncology, Vol. 57, Iss. 1, 1999-07 ,pp. : 10-16

Karger

Access to resources Recommend Favorite

Dose Escalation of Carboplatin and Cyclophosphamide Supported by GM-CSF in the Treatment of Patients with Advanced Ovarian Cancer (FIGO III and IV) – a Phase I Study

By  

Oncology Research and Treatment, Vol. 22, Iss. 6, 2000-01 ,pp. : 502-506

Karger

Access to resources Recommend Favorite